These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 546671)

  • 1. [Pharmacokinetic study in the rat of a new hypoglycemic agent: glisolamide].
    Cerri L; Dalla Vedova R; Groppetti A
    G Clin Med; 1979 Nov; 60(11):903-10. PubMed ID: 546671
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and metabolism of 14C-glipentide, a new antidiabetic, after oral and intravenous administration.
    Chanal JL; Calmette MT; Khiat M; Rimbau V; Vera A
    Arzneimittelforschung; 1977; 27(4):852-6. PubMed ID: 577463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a new hypoglycemic agent SPC-703.
    Jakubowski Z; Angielski S
    Pol J Pharmacol Pharm; 1980; 32(2):165-72. PubMed ID: 7454622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex difference in pharmacokinetics of the novel sulfonylurea antidiabetic glimepiride in rats.
    Yamazaki H; Tabata S
    Arzneimittelforschung; 1993 Dec; 43(12):1317-21. PubMed ID: 8141820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of glibornuride].
    Rentsch G; Schmidt HA; Rieder J
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2209. PubMed ID: 4679250
    [No Abstract]   [Full Text] [Related]  

  • 6. [Glisolamide, a new sulfanylurea. Pharmacologic characteristics].
    D'Alò G; Dalla Vedova R; Cadel S; Campi G; Wassermann A
    Boll Chim Farm; 1978 Jun; 117(6):348-67. PubMed ID: 743381
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotransformation of a new hypoglycemic agent, N-(p-toluenesulfonyl)-5-methyl-2-pyrazoline-1-carbonamide (SPC-703) in humans and rats.
    Jakubowski Z; Angielski S
    Pol J Pharmacol Pharm; 1980; 32(1):37-46. PubMed ID: 7454610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human pharmacokinetics and metabolism of 14C-labeled gliquidone (AR-DF 26)].
    Kopitar Z
    Arzneimittelforschung; 1975 Sep; 25(9):1455-60. PubMed ID: 1103897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of the protective activity of glisolamide on experimental atherosclerosis in the rabbit].
    Dalla Vedova R; Cadel S; D'Alò G
    G Clin Med; 1979 Nov; 60(11):911-26. PubMed ID: 546672
    [No Abstract]   [Full Text] [Related]  

  • 10. [Oral antidiabetics of the sulfonylurea group and their problems in therapy].
    Füsgen I; Summa JD
    Z Gerontol; 1980; 13(1):45-51. PubMed ID: 7456613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Influence of deficient kidney function on behavior of glipizide (hypoglycemic sulfonylurea) and its metabolites].
    Fabre J; Balant L; Zahnd G
    J Urol Nephrol (Paris); 1973; 79(4):380-1. PubMed ID: 4720133
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of glipizide in man: influence of renal insufficiency.
    Balant L; Zahnd G; Gorgia A; Schwarz R; Fabre J
    Diabetologia; 1973 Sep; ():331-8. PubMed ID: 4772979
    [No Abstract]   [Full Text] [Related]  

  • 13. Emergency management of oral hypoglycemic drug toxicity.
    Rowden AK; Fasano CJ
    Emerg Med Clin North Am; 2007 May; 25(2):347-56; abstract viii. PubMed ID: 17482024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolism of glibornuride in the human].
    Bigler F; Quitt P; Vecchi M; Vetter W
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2191. PubMed ID: 4679249
    [No Abstract]   [Full Text] [Related]  

  • 15. [Experimental studies on the mechanism of thrombocyte aggregation inhibition caused by sulfonylurea compounds. 2. Modification of blood sugar and thrombocyte aggregation by oral antidiabetics].
    Losert W; Hoder A; Scholz C
    Arzneimittelforschung; 1975 Feb; 25(2):170-9. PubMed ID: 804311
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of some salicylates and sulfonamides on binding by albumin of SPC-703 and tolbutamide.
    Wójcikowski C; Szlabowicz D
    Pol J Pharmacol Pharm; 1976; 28(2):129-35. PubMed ID: 945561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of radioactively labeled glisoxepide in the animal].
    Kolb KH; Schulze PE; Speck U; Acksteiner B
    Arzneimittelforschung; 1974 Mar; 24(0):397-403. PubMed ID: 4211553
    [No Abstract]   [Full Text] [Related]  

  • 18. [Potentiation of the hypoglycemic effect of sulfonylurea derivatives by drugs. II. Pharmacokinetics and metabolism of glibenclamide (HB 419) in presence of phenylbutazone].
    Schulz E; Koch K; Schmidt FH
    Eur J Clin Pharmacol; 1971 Dec; 4(1):32-7. PubMed ID: 5004903
    [No Abstract]   [Full Text] [Related]  

  • 19. [Glibornuride, a new high-effective antidiabetic agent. Pharmacological and biochemical comparative studies in various animal species and animal experimental models].
    Lorch E; Gey KF; Sommer P
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2154. PubMed ID: 4198964
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of 3H-glibenclamide binding to sulfonylurea receptors by oral antidiabetics.
    Geisen K; Hitzel V; Okomonopoulos R; Pünter J; Weyer R; Summ HD
    Arzneimittelforschung; 1985; 35(4):707-12. PubMed ID: 3925960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.